We are excited to announce that Biointron, a leading high-tech enterprise specializing in antibody discovery and expression, has successfully raised $370 million in its latest funding round. Founded in 2012 and certified to ISO 9001:2015, Biointron has established itself as a trailblazer in providing innovative, one-stop antibody discovery services. With over 1,500 clients spanning 20 countries, our commitment to accelerating the antibody discovery process is evident in our fully automated production processes and adherence to international standards.
This substantial infusion of capital will be pivotal in expanding our research and development capabilities, enabling us to enhance our existing services while also exploring groundbreaking technologies in antibody production and optimization. Key areas of focus will include advancing our VHH production, hybridoma sequencing, and single B cell screening processes. Additionally, the funding will support the global commercialization of our proprietary CHO-K1 cell line, which is in compliance with international multicenter requirements and is already recognized by the U.S. FDA's DMF. This progress opens doors for our partners, allowing their projects to move into the international clinical stage with confidence.
At Biointron, we believe this funding will help us further our mission to deliver cutting-edge antibody solutions to the biopharmaceutical industry, ultimately contributing to advancements in healthcare worldwide. We invite you to learn more about our journey and initiatives by visiting our official website at www.biointron.com or reaching out to us at info@biointron.com. Thank you for being part of this exciting chapter!
